ZONAGEN VASOMAX NDA SLATED FOR JUNE FILING; FAST NDA ASSEMBLY ATTRIBUTED TO CRO/SMO PARTNERSHIP; LILLY CALLS CRO USE "MINOR" PART OF PROCESS IMPROVEMENTS
Executive Summary
Zonagen is expecting to file an NDA for its erectile dysfunction compound Vasomax (phentolamine) by the end of June, just short of one year after its IND filing, Zonagen President Joseph Podolski said at an April 14-16 Institute for International Research meeting on partnerships with contract research organizations in Scottsdale, Ariz.